Skip to main content

The Complementary Plan for Biotechnology applied to Health will promote high-throughput screening projects to accelerate the discovery of new drugs



Press & Communications Section Head
Tel.+34 93 40 37255
  • On March 27, the call for expressions of interest “SCREENTECH” will be opened within the Complementary Plan for Biotechnology in Catalonia. This initiative will prioritize the development of new projects on IRB Barcelona’s drug screening and drug-target interaction analysis platform.

The objective of Action Line 3 (LA3) of the Complementary Plan for Biotechnology applied to Health – coordinated by IBEC- is to develop an integrated high-throughput screening system through IRB Barcelona’s “drug screening and drug-target interaction analysis platform“. This system aims to support research projects that will allow the identification and optimization of new compounds that can be used in general and precision medicine, as well as in the repositioning of drugs for new applications. 

At the regional level, Catalonia will count on the Institute for Research in Biomedicine (IRB Barcelona) node to carry out high-throughput screenings and drug-target interaction studies, and to this end, a reinforcement on its drug screening platform is planned. In this way, a series of actions will be carried out to increase its processing and data analysis capacity. In addition, it will be equipped with cutting-edge technologies in biological monitoring and highly qualified personnel will be hired. Thanks to this strengthening, this platform will promote unique translational services in an affordable, collaborative, and open framework to the entire scientific community. 

In this context, on March 27, the SCREENTECH program will be opened, with a call for expressions of interest (EdI) for high-performance screenings using this platform.  

This call is co-financed by the Recovery, Transformation and Resilience Plan (PRTR C17.I1), the European Union Next Generation EU and the Autonomous Community of Catalonia. It is aimed at Catalan agents, public or private, non-profit, who carry out scientific and technical research activities focused on personalized medicine.

A total budget of € 452,000 will be assigned, with a maximum amount of  € 56,500 per selected EdI, until the budget is exhausted.  

The deadline for submission of the EdI will be from March 27 to May 2, 2023 at 23:59 (Spanish peninsular time).  

More details here

About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).